Study of abnormal avtivity and mutation of tyrosine kinases in Hypereosinophilic syndrome.

Study of abnormal avtivity and mutation of tyrosine kinases in Hypereosinophilic syndrome. - Study of abnormal tyrosine kinase expression in HES.

Status

Active, not recruiting

Phases

Unknown

Study type

Observational

Source

JPRN

Registry ID

JPRN-UMIN000008655

Enrollment

Registered

2012-08-15

Start date

2008-10-01

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Hypereosinophilic syndrome,chronic eosinophilic leukemia

Interventions

None listed

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Imatinib treated HES/CEL without F/P fusion gene, and Imatinib resistant CEL with F/P fusion gene.

Exclusion criteria

Exclusion criteria: Corticosteroid or Antiallergic drug effective HES

Design outcomes

Primary

Measure	Time frame
Exploration of novel biomarkers in HES/CEL	—

Secondary

Measure	Time frame
Function analysis of the newly explored biomakers	—

Countries

Japan

Contacts

Public ContactAkiko Sada

Kobe University Graduate School of Medicine Division of Hematology,Department of Medicine

akikosad@med.kobe-u.ac.jp078-382-6912

Outcome results